Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azelastine/fluticasone propionate - Cipla/Meda

Next Previous
Drug Profile

Azelastine/fluticasone propionate - Cipla/Meda

Alternative Names: Azelastine hydrochloride/fluticasone propionate; Duonase; Dymista; Dymista D; Dymistalan; Dymistin; Dymolin; Fluticasone propionate/azelastine hydrochloride; Flutista; MP 29-01; MP 29-02; MP-AzeFlu

Latest Information Update: 20 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meda
  • Developer Cipla; Meda; Mylan
  • Class Antiallergics; Glucocorticoids; Phthalazines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 27 Oct 2021 Launched for Allergic rhinitis in Taiwan, Thailand (Intranasal) (NCT05158972)
  • 01 Oct 2021 Registered for Allergic rhinitis in Taiwan, Thailand (Intranasal) (NCT05158972)
  • 01 Aug 2019 No development reported - Preregistration for Allergic rhinitis in China, South Africa, Middle East (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top